Pharmacotherapeutic approach toward urological medications and vaccination during COVID-19: a narrative review

• Main Authors: Mojtaba Shafiekhani, Anahita Dehghani, Mina Shahisavandi, Seyed Ali Nabavizadeh, Maryam Kabiri, Amir Hossein Hassani, Abdolreza Haghpanah
• Format: Article
• Language: English
• Published: SAGE Publishing 2021-09-01
• Series: Therapeutic Advances in Urology
• Online Access: https://doi.org/10.1177/17562872211046794

One year after the prevalence of the novel coronavirus pandemic, some aspects of the physiopathology, treatment and progression of coronavirus 2019 disease (COVID-19) have remained unknown. Since no comprehensive study on the use of urological medications in patients with COVID-19 has been carried out, this narrative review aimed to focus on clinically important issues about the treatment of COVID-19 and urologic medications regarding efficacy, modifications, side effects and interactions in different urologic diseases. In this review, we provide information about the pharmacotherapeutic approach toward urologic medications in patients with COVID-19 infection. This study provides an overview of medications in benign prostatic hyperplasia, prostate cancer, impotence and sexual dysfunction, urolithiasis, kidney transplantation and hypertension as the most frequent diseases in which the patients are on long-term medications. Also, the effect of urologic drugs on the efficacy of vaccination is briefly discussed.